Amgen: DeLLphi-305 trial shows significant survival benefit for IMDELLTRA plus IMFINZI
According to TradingView, in DeLLphi-305 IMDELLTRA with IMFINZI improved overall survival, PFS and ORR versus IMFINZI alone.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, in the DeLLphi-305 trial, first-line maintenance treatment with IMDELLTRA combined with IMFINZI significantly improved overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared with IMFINZI alone in extensive-stage small cell lung cancer.
The broader program is still testing earlier use of the drug, alternative dosing schedules and additional tumor types.
why it matters
The news mainly concerns Amgen, as strong data for an oncology drug can support investor interest in the company and its cancer pipeline. The report is based on a short AI-generated summary from TradingView, so key details should be checked against the original source.
market impact
Amgen: strong drug data may support investor interest in the company's shares
tags
instruments
sources
- AMGN: DeLLphi-305 showed a significant survival benefit for first-line maintenance IMDELLTRA plus IMFINZI — TradingView, 24 October 2026 at 18:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗